Europe’s biosimilars market now has many years of progress under its belt. But how can this successful foundation be built upon to make the most of the opportunities on the horizon and achieve even greater access and uptake? In an exclusive interview, Generics Bulletin talks to Medicines for Europe’s Isabell Remus and Julie Maréchal-Jamil about the next steps.

Teva is ramping up its activities in US biosimilars, with the launch of its Alvotech-partnered Humira rival imminent and a Stelara biosimilar slated for launch in February 2025. Tom Rainey, the firm’s senior vice president of US market access, talks about the opportunities on the horizon and how the firm is balancing its partnership model with in-house development.